Toll‐Like Receptor 8 Agonist GS‐9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B

BACKGROUND AND AIMS: GS‐9688 (selgantolimod) is an oral selective small molecule agonist of toll‐like receptor 8 in clinical development for the treatment of chronic hepatitis B. In this study, we evaluated the antiviral efficacy of GS‐9688 in woodchucks chronically infected with woodchuck hepatitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Daffis, Stephane, Balsitis, Scott, Chamberlain, Jason, Zheng, Jim, Santos, Rex, Rowe, William, Ramakrishnan, Dhivya, Pattabiraman, Divya, Spurlock, Sandra, Chu, Ruth, Kang, Don, Mish, Michael, Ramirez, Ricardo, Li, Li, Li, Bei, Ma, Sarina, Hung, Magdeleine, Voitenleitner, Christian, Yon, Changsuek, Suresh, Manasa, Menne, Stephan, Cote, Paul, Delaney, William E., Mackman, Richard, Fletcher, Simon P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898792/
https://www.ncbi.nlm.nih.gov/pubmed/32246499
http://dx.doi.org/10.1002/hep.31255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898792/
https://www.ncbi.nlm.nih.gov/pubmed/32246499
http://dx.doi.org/10.1002/hep.31255

Ejemplares similares